Pharmexa Loses Bid To Restore Broad Patent Claims

Law360, New York (September 4, 2007, 12:00 AM EDT) -- An appeal board of the European Patent Office has upheld a ruling to revoke the broad patent claims of Danish pharmaceutical giant Pharmexa A/S over a cancer treatment.

Geron Corp., a rival biotech company, said Tuesday the Technical Board of Appeal of the EPO invalidated the claims of a European patent filed by Pharmexa in 2003, finding that they were overbroad and infringed claims patented by Geron.

The Pharmexa patent covered the use of telomerase peptides and nucleic acids for cancer immunotherapy.

Geron, based in Menlo...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.